4.08

2.90% 0.11

Inovio Pharmaceuticals Inc (INO)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Frazionamento azionario

Precedente Chiudi:

$3.97

Aprire:

$4.01

Volume 24 ore:

454.86K

Relative Volume:

1.43

Capitalizzazione di mercato:

$108.60M

Reddito:

$832.00K

Utile/perdita netta:

$-135.12M

Rapporto P/E:

-6.2769

EPS:

-0.65

Flusso di cassa netto:

$-124.69M

1 W Prestazione:

-14.36%

1M Prestazione:

-28.83%

6M Prestazione:

-62.83%

1 anno Prestazione:

-18.60%

Intervallo 1D:

$3.97

$4.24

Intervallo di 1 settimana:

$3.85

$4.97

Portata 52W:

$3.85

$14.75

Inovio Pharmaceuticals Inc Stock (INO) Company Profile

Nome

Inovio Pharmaceuticals Inc

Settore

Healthcare (1195)

Industria

Biotechnology (683)

Telefono

(858) 410-3134

Indirizzo

6769 MESA RIDGE RD., SAN DIEGO, PA

Dipendente

122

Cinguettio

@inoviopharma

Prossima data di guadagno

2024-11-07

Ultimi documenti SEC

INO's Discussions on Twitter

Confronta INO con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
INO	4.0893	108.60M	832.00K	-135.12M	-124.69M	-0.65
VRTX	449.99	115.43B	10.63B	-479.80M	-1.35B	13.33
REGN	747.50	82.04B	13.85B	4.65B	3.32B	35.06
ARGX	593.04	35.30B	1.86B	-40.29M	-1.28B	-4.16
ALNY	246.22	32.04B	2.09B	-332.26M	16.06M	-4.14
BNTX	107.19	24.89B	3.30B	-501.07M	1.03B	11.54

Inovio Pharmaceuticals Inc Stock (INO) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2022-11-09	Downgrade	Maxim Group	Buy → Hold
2022-11-01	Downgrade	BofA Securities	Neutral → Underperform
2022-07-19	Ripresa	RBC Capital Mkts	Sector Perform
2022-05-11	Downgrade	Oppenheimer	Outperform → Perform
2022-01-21	Aggiornamento	BofA Securities	Underperform → Neutral
2021-12-29	Ripresa	Jefferies	Hold
2021-09-10	Downgrade	BofA Securities	Neutral → Underperform
2021-06-24	Iniziato	Jefferies	Hold
2021-03-23	Iniziato	BofA Securities	Neutral
2021-02-12	Iniziato	Oppenheimer	Outperform
2020-11-17	Downgrade	ROTH Capital	Neutral → Sell
2020-11-10	Aggiornamento	ROTH Capital	Sell → Neutral
2020-09-28	Downgrade	Cantor Fitzgerald	Overweight → Neutral
2020-09-28	Aggiornamento	Maxim Group	Hold → Buy
2020-07-01	Downgrade	Maxim Group	Buy → Hold
2020-07-01	Downgrade	ROTH Capital	Neutral → Sell
2020-06-29	Downgrade	H.C. Wainwright	Buy → Neutral
2020-06-26	Downgrade	Stifel	Buy → Hold
2020-05-21	Iniziato	The Benchmark Company	Buy
2020-04-30	Downgrade	ROTH Capital	Buy → Neutral
2020-03-13	Downgrade	Piper Sandler	Overweight → Neutral
2020-03-13	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2019-12-19	Iniziato	ROTH Capital	Buy
2018-02-15	Reiterato	Maxim Group	Buy
2017-10-18	Iniziato	RBC Capital Mkts	Outperform
2017-09-06	Iniziato	Citigroup	Buy
2017-06-08	Aggiornamento	Piper Jaffray	Neutral → Overweight
2017-05-24	Reiterato	Maxim Group	Buy
2017-03-16	Aggiornamento	Maxim Group	Hold → Buy
2017-03-16	Downgrade	Piper Jaffray	Overweight → Neutral

Mostra tutto

Inovio Pharmaceuticals Inc Borsa (INO) Ultime notizie

Nov 20, 2024

Inovio Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch

Nov 20, 2024

INOVIO Set to Unveil Q3 2024 Financial Results and Business Insights on November 14! - MSN

Nov 20, 2024

July 25, 2024 - Site Selection Magazine

Nov 20, 2024

What is HC Wainwright's Estimate for INO FY2024 Earnings? - MarketBeat

Nov 20, 2024

Nov 19, 2024

Inovio Pharmaceuticals (LTS:0A43) Debt-to-Equity : 0.13 (As of Jun. 2024) - GuruFocus.com

Nov 19, 2024

Inovio Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch

Nov 19, 2024

INOVIO Reports Third-Quarter Financial Results and Updates on INO-3107 Progress - MyChesCo

Nov 19, 2024

Nov 18, 2024

The Analyst Landscape: 4 Takes On Inovio Pharmaceuticals - Benzinga

Nov 18, 2024

Inovio Pharmaceuticals (NASDAQ:INO) Price Target Cut to $5.00 by Analysts at HC Wainwright - MarketBeat

Nov 18, 2024

INOVIO Announces Promising Immunology Data for INO-3107 in RRP Treatment - MyChesCo

Nov 18, 2024

Inovio stock hits 52-week low at $4.15 amid market challenges - Investing.com Nigeria

Nov 18, 2024

Inovio Pharmaceuticals (NASDAQ:INO) Given New $15.00 Price Target at Oppenheimer - MarketBeat

Nov 18, 2024

Inovio shares target cut by Oppenheimer, retains outperform on Q3 results - Investing.com UK

Nov 18, 2024

Nov 17, 2024

Inovio Pharma Stock Slips Ahead of Q3 Earnings: Retail’s Bullish - MSN

Nov 17, 2024

Inovio focused on launching global COVID-19 vaccine trial next month - The Jerusalem Post

Nov 17, 2024

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Nov 17, 2024

Nov 16, 2024

Inovio Pharmaceuticals Third Quarter 2024 Earnings: US$0.89 loss per share (vs US$1.52 loss in 3Q 2023) - Yahoo Finance

Nov 16, 2024

Inovio to begin mid-stage study of COVID-19 vaccine candidate - Reuters

Nov 16, 2024

Nov 15, 2024

Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch

Nov 15, 2024

Royal Bank of Canada Cuts Inovio Pharmaceuticals (NASDAQ:INO) Price Target to $6.00 - MarketBeat

Nov 15, 2024

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 15, 2024

Inovio: Q3 Earnings Snapshot - mySA

Nov 15, 2024

Q3 2024 Inovio Pharmaceuticals Inc Earnings Call Transcript - GuruFocus.com

Nov 15, 2024